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Bordetella parapertussis PagP Mediates the Addition of Two Palmitates
to the Lipopolysaccharide Lipid A
L. E. Hittle,a J. W. Jones,b A. M. Hajjar,c R. K. Ernst,a A. Prestond
Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, Maryland, USAa; Department of Pharmaceutical Sciences, University of
Maryland School of Pharmacy, Baltimore, Maryland, USAb; Department of Comparative Medicine, School of Medicine, University of Washington, Seattle, Washington,
USAc; Department of Biology and Biochemistry, University of Bath, Bath, United Kingdomd
Bordetella bronchiseptica PagP (PagPBB) is a lipid A palmitoyl transferase that is required for resistance to antibody-dependent
complement-mediated killing in a murine model of infection. B. parapertussis contains a putative pagP homolog (encoding B.
parapertussis PagP [PagPBPa]), but its role in the biosynthesis of lipid A, the membrane anchor of lipopolysaccharide (LPS), has
not been investigated. Mass spectrometry analysis revealed that wild-type B. parapertussis lipid A consists of a heterogeneous
mixture of lipid A structures, with penta- and hexa-acylated structures containing one and two palmitates, respectively. Through
mutational analysis, we demonstrate that PagPBPa is required for the modification of lipid A with palmitate. While PagPBB trans-
fers a single palmitate to the lipid A C-3= position, PagPBPa transfers palmitates to the lipid A C-2 and C-3= positions. The addi-
tion of two palmitate acyl chains is unique to B. parapertussis. Mutation of pagPBPa resulted in a mutant strain with increased
sensitivity to antimicrobial peptide killing and decreased endotoxicity, as evidenced by reduced proinflammatory responses via
Toll-like receptor 4 (TLR4) to the hypoacylated LPS. Therefore, PagP-mediated modification of lipid A regulates outer mem-
brane function andmay be a means to modify interactions between the bacterium and its human host during infection.
The genus Bordetella contains nine species, three of which havebeen studied in detail: B. pertussis, B. parapertussis, and B.
bronchiseptica. B. pertussis and B. parapertussis are the causative
agents of whooping cough. While long considered a disease of
infants and children, it is now recognized that infections occur in
adults, although they are milder than the classic whooping cough
described in children (1–5). B. pertussis is considered the major
pathogen of whooping cough; however, the prevalence of B.
parapertussis in disease is not well understood but may be a signif-
icant contributor to the overall burden (6). Symptoms ofB. parap-
ertussis and B. pertussis disease are clinically indistinguishable and
include a prolonged cough, whooping, paroxysms, vomiting, and
cyanosis (7), leading to increased mortality in infected children;
however, B. parapertussis is often considered to cause milder dis-
ease than B. pertussis (7). In many countries, whooping cough is
controlled by vaccination against B. pertussis. However, many
countries have recently suffered major outbreaks despite contin-
uous high levels of vaccine coverage, initiating renewed interest in
whooping cough vaccinology. The acellular pertussis vaccines
(DTaP and Tdap) used in most developed countries do not result
in protection against B. parapertussis, likely due to the B. paraper-
tussis lipopolysaccharide (LPS) O antigen inhibiting the binding
of antibodies to the bacterium (8).
LPS is the major component of the outer leaflet of the outer
membrane of Gram-negative bacteria. The lipid A region imparts
the endotoxin activity of LPS (9) that arises when lipid A binds to
a host membrane complex that includes and activates signaling by
Toll-like receptor 4 (TLR4) (10), resulting in the expression of
many proinflammatory cytokines and chemokines in cells of the
innate immune system. TLR4 signaling is also important for the
activation of adaptive immunity, particularly through the activa-
tion of dendritic cells (DCs), which act as antigen-presenting cells
(APCs) for T cells. Thus, lipid A-TLR4 interactions are central to
the host immune response to Gram-negative bacteria, including
Bordetella species.
Bordetella subspecies exhibit extensive heterogeneity in their
lipid A structure, arising from both species-specific differences in
and species-variable expression of specific lipid A-modifying en-
zymes (11, 12). Previously, we demonstrated thatB. bronchiseptica
pagP (pagPBB) encodes a lipid A palmitoyl transferase that is re-
sponsible for the presence of palmitate in lipid A. The expression
of pagPBB is regulated by the Bvg two-component system (13) that
regulates the expression of manyBordetella genes that are involved
in pathogenesis (14). pagPBB is maximally expressed in the Bvg-
plus (Bvg) phase that is adopted when the system is active and
includes the expression of many of the toxins and adhesins con-
sidered important for infection. When the Bvg system is inactive,
the bacteria adopt the Bvg-minus (Bvg) phase, and the expres-
sion of these virulence genes is downregulated. Thus, the Bvg
and Bvg phases are regarded as the states that the bacteria adopt
upon entering the host respiratory tract and the environment,
respectively (14). We also showed that pagPBB is required for the
persistence of B. bronchiseptica within the mouse respiratory tract
through resistance to antibody-dependent complement-medi-
ated killing (13, 15). This represented the first description of a
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direct role for the pagP gene in virulence for Bordetella. B. parap-
ertussis also contains a pagP gene, but B. parapertussis lipid A con-
tains two secondary palmitates, compared to a single palmitate
residue in B. bronchiseptica (16). Here we present characterization
of B. parapertussis pagP (pagPBPa), its role in lipid A biosynthesis,
and the role of lipid A palmitoylation in B. parapertussis outer
membrane function.
MATERIALS AND METHODS
Bacterial strains and plasmids. Escherichia coli XL1-Blue (Agilent Tech-
nologies, Wokingham, United Kingdom) or Top10 (Invitrogen Life Tech-
nologies, Paisley, United Kingdom) cells were used for cloning and main-
tenance of plasmids. E. coli SM10pir (17) or CC118pir was used as the
donor strain in conjugations. The pCR2.1 Topo or pCR8 Gateway entry
vector (Invitrogen Life Technologies) was used to clone PCR products.
pEX100T (18) was used as a suicide vector for allelic-exchange mutagen-
esis in B. parapertussis. pBBR1kan is a derivative of pBBR1MCS in which
the chloramphenicol resistance cassette has been replaced with a kanamy-
cin resistance cassette. pBBR1MCS is a broad-host-range vector that is
capable of replication in Bordetella (19). pBBR1kan was used to introduce
a plasmid-borne pagP gene into the B. parapertussis wild type (WT) and
the pagP mutant.
Bacterial growth media and conditions. B. parapertussis was grown
on charcoal agar (BD, Oxford, United Kingdom) at 37°C. E. coli was
grown on LB agar at 37°C. For liquid culture,B. parapertussiswas grown in
Stainer-Scholte broth (20) modified by the addition of Casamino Acids
(50g liter1) at 37°C with shaking, and E. coli was grown in LB broth at
37°C with aeration. For growth of B. parapertussis in the Bvg phase,
MgSO4 was added to growth medium to a concentration of 50 mM. Strep-
tomycin (200 g ml1), ampicillin (100 g ml1), erythromycin (10 g
ml1), and kanamycin (50 g ml1) were used where appropriate.
Chemicals and reagents. Chemicals and reagents were obtained from
BD, Fisher Scientific (Loughborough, United Kingdom), or Sigma-Al-
drich (Gillingham, United Kingdom).
DNA purification. Plasmid DNA was purified by using an Invitrogen
plasmid DNA purification kit according to the manufacturer’s instruc-
tions. Genomic DNA was purified by using the agarose plug method (21).
DNA manipulation. DNA manipulations were performed according
to standard methods. DNA restriction and modifying enzymes were ob-
tained from New England BioLabs (Hitchin, United Kingdom), Roche
(Burgess Hill, United Kingdom), or Invitrogen Life Technologies.
PCR and primers. A genomic DNA template was made by resuspend-
ing plate-grown bacteria in 0.5 ml of water, boiling in a water bath for 5
min, spinning at top speed in a bench-top microcentrifuge for 2 min, and
taking 0.2 ml of the supernatant. One microliter of supernatant was used
per PCR. Each 50-l PCR mixture was comprised of the genomic DNA
template, buffer as directed by the manufacturer, deoxynucleoside
triphosphates (dNTPs) (25 M each), 20 ng of each primer, 5% (vol/vol)
dimethyl sulfoxide (DMSO), 5 mM MgCl2, and 2.5 units of Taq DNA
polymerase (Promega, Southampton, United Kingdom). Primers used to
amplify the B. parapertussis pagP locus were PagPF (5=-CTCCGCATTCC
AGGTAGGCC-3=) and PagPR (5=-TTAGAACTCCCAGCGGCCAAAC-
3=). PCR mixtures were incubated at 94°C for 5 min followed by 30 cycles
of 94°C for 75 s, 60°C for 75 s, and 72°C for 90 s, followed by a final step at
72°C for 7 min.
Conjugations. Conjugations were performed as described previously
(22).
Complementation of the pagP mutation. The region encompassing
the putative pagP promoter and the pagP coding sequence was amplified
from either B. parapertussis or B. bronchiseptica by PCR, and the PCR
product was cloned into the pCR8/GW/Topo cloning vector. The insert
was subcloned into pBBR1kan that had been modified to a Gateway des-
tination vector by using the Invitrogen Gateway cloning system. This con-
struct was introduced into B. parapertussis by conjugation.
SDS-PAGE/silver stain analysis of LPS. Whole-cell-lysate LPS sam-
ples were prepared and analyzed by sodium dodecyl sulfate (SDS)-PAGE/
silver staining, as previously described (23).
Peptide killing assays. Bacteria were grown on agar plates for 3 days
and then resuspended in phosphate-buffered saline (PBS). The suspen-
sions were diluted to 104 bacteria/190l. Ten microliters of PBS contain-
ing C18G at a final concentration of 0, 1, 2.5, 5, or 10 g ml1 was added
to each suspension, which was then incubated at 37°C for 30 min. Each
peptide concentration was tested in triplicate. Suspensions were serially
diluted in PBS, and 100 l of dilutions was plated onto agar. Plates were
incubated at 37°C for 3 days, and colonies were counted to enumerate the
bacteria that had survived the assay. Differences in the numbers of surviv-
ing WT and mutant bacteria were compared by using a Student t test. The
experiment was performed three times.
TLR4 stimulation assays. Reporter cell lines and stimulation assays
were performed as described previously (20).
LipidA structural analyses. (i)Matrix-assisted laser desorption ion-
ization–timeofflight/timeofflightmass spectrometry.LPS was purified
from 1 liter of cultures grown overnight, as described previously (24).
Further treatment of LPS with RNase A, DNase I, and proteinase K en-
sured the removal of contaminating nucleic acids and proteins (25). Hy-
drolysis of LPS to isolate lipid A was accomplished with 1% SDS at pH 4.5,
as described previously (26).
Lipid A was analyzed by matrix-assisted laser desorption ionization
(MALDI) in the negative-ion mode on a 4700 proteomics analyzer (Ap-
plied Biosystems, Framingham, MA). Samples were dissolved in 10l of a
mixture of 5-chloro-2-mercaptobenzothiazole (20 mg ml1) in chloro-
form-methanol-water (4:4:1, vol/vol/vol), and 0.5 l of the sample was
analyzed by MALDI-time of flight/time of flight mass spectrometry (TOF/
TOF MS). Both MS and tandem MS (MS/MS) data were acquired in the
reflectron mode with a neodymium-doped yttrium aluminum garnet
(Nd:YAG) laser with a 200-Hz repetition rate, and up to 4,000 shots were
accumulated for each spectrum. The precursor isolation window was set
to5 Da. Tandem MS spectra were acquired with collision energies of 1
keV, and air was used as the collision gas. Instrument calibration and all
other tuning parameters were optimized by using HP Calmix (Sigma-
Aldrich, St. Louis, MO). Data were acquired and processed by using Data
Explorer (Applied Biosystems, Framingham, MA).
(ii) Electrospray ionization linear ion trap Fourier transform ion
cyclotron resonance mass spectrometry. Lipid A was analyzed by elec-
trospray ionization (ESI) in the negative-ion mode on an linear trap qua-
drupole Fourier transform (LTQ-FT) mass spectrometer (Thermo Fisher,
San Jose, CA). Samples were diluted to0.5 to 1.0 mg/ml in chloroform-
methanol (1:1) and infused at a rate of 1.0 l/min via a fused silica capil-
lary (75-m internal diameter [i.d.]; 360-m outside diameter [o.d.])
with an 30-m spray tip (New Objective, Woburn, MA). Instrument
calibration and tuning parameters were optimized by using a solution
of Ultramark 1621 (Lancaster Pharmaceuticals, PA). For experiments
acquired in the ion cyclotron resonance (ICR) cell, resolution was set
to 100K, and ion populations were held constant by automatic gain
control at 1.0  106 and 5.0  105 for MS and MS/MS, respectively.
For tandem mass spectra, the precursor ion selection window was set
to 5 Da, and the collision energy was set to 30% on the instrument
scale. Data from the collision-induced dissociation (CID) MSn analysis
(where n represents the number of times an ion was subjected to MS)
in the linear ion trap were acquired with an ion population of 1.0 104
and a maximum fill time of 200 ms. The subsequent MS3 and MS4
events had an isolation window of 4 Da with a collision energy of 25%.
All spectra were acquired over a time period of 1 min and averaged. MS
and MS2 events were mass analyzed in the ICR cell, and MS3 and MS4
events were mass analyzed in the LTQ instrument. Data were acquired
and processed by using Xcalibur, version 1.4 (Thermo Fisher), utiliz-
ing 7-point Gaussian smoothing.
B. parapertussis pagP
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RESULTS
Identification of pagPBPa. pagPBPa was identified by genome se-
quence analysis using the PagPBB sequence (Swiss-Prot database
accession number Q7WFT9.1). TheB. parapertussis andB. pertus-
sis genes were found to be nearly identical at the DNA level in both
the promoter and coding sequence. A single G:A base change in
the middle position of the 24th codon was observed, which re-
sulted in an aspartate in PagPBPa, compared to a glycine in PagPBB.
To investigate the role of pagP in overall LPS biosynthesis in B.
parapertussis, a B. parapertussis pagP mutant was constructed and
analyzed by using SDS-PAGE to determine the LPS profile com-
pared to that of the WT (Fig. 1).
In these analyses, two main LPS types are visible: lipid A-core
LPS and lipid A-core that is further substituted with O polysac-
charide (O PS). The WT LPS profile differed between the Bvg
and Bvg phases. In the plus phase, core-lipid A LPS migrated as a
diffuse smear, indicative of a heterogeneous nature of LPS struc-
tures being present in this region. The O PS-containing LPS sep-
arated as a series of bands, demonstrating that LPS molecules that
differ in the number of O PS repeats were well separated (Fig. 1,
lane 1). In the Bvg phase, the O PS migrated as a compacted
series of bands due to the action of the Bvg-phase enzyme
WbmE, which deaminates some of the O PS uronamide sugars
(27). In addition, the core-lipid A LPS was present as a single
intense band and just one or two other very faint bands, suggesting
that a restricted number of core-lipid A structures were expressed
in the minus phase compared to the plus phase (Fig. 1, lane 2).
The LPS profile of the pagPBPa mutant differed from that of the
WT in the core-lipid A region. In the Bvg phase, the mutant
profile comprised a doublet with near-equal-intensity bands,
whereas in the minus phase, a single band was observed (Fig. 1,
lanes 3 and 4). This suggests that PagPBPa expression is required
for some of the core-lipid A structures observed in the WT and
that Bvg activity affects the expression of PagP-dependent LPS
structures. Importantly, these analyses demonstrate that mutant
structures are incorporated into mature LPS and are likely incor-
porated into the outer membrane. This is important for interpret-
ing the phenotype of the pagPBPa mutant (see below).
To confirm the role of pagPBPa in LPS biosynthesis, the pagP
mutation was complemented in trans by expressing pagP from a
plasmid using the native pagP promoter. The LPS profile of the
complemented mutant in the Bvg phase comprised three well-
resolved core-lipid A bands (Fig. 1, lane 6). This is different from
the WT profile. We hypothesized that the multicopy nature of
carrying the complementing gene on a plasmid was responsible
for this difference. Thus, the complemented mutant profile was
compared to that of the WT carrying the plasmid copy of pagP
(Fig. 1, lane 5) and found to be the same. These data support the
conclusion that the loss of core-lipid A bands from the profile of
the pagPBPa mutant was due to a mutation of pagP (see also be-
low).
Mass spectrometric analysis of lipid A isolated from WT B.
parapertussis LPS. To define the specific structural differences
between WT and mutant LPS structures, lipid A was purified from
both strains and analyzed by mass spectrometry (MS). MALDI
TOF/TOF and ESI LTQ-FT MS platforms were used to gain com-
prehensive structure determination. The negative-ion-mode
MALDI-TOF mass spectrum of lipid A isolated from WT B.
parapertussis LPS is shown in Fig. 2A. The most abundant ion, at
m/z 1,332 (Fig. 2A), corresponded to a singly deprotonated lipid A
structure that contained two phosphate groups and four acyl
chains (i.e., diphosphoryl tetra-acylated lipid A). Two other
prominent singly charged ions were recorded at m/z values of
1,570 (diphosphoryl penta-acylated lipid A) and 1,808 (diphos-
phoryl hexa-acylated lipid A). The ions at m/z 1,570 and 1,808
differed from the ion at m/z 1,332 by the addition of one and two
secondary palmitate (C16) acyl chains, respectively. The proposed
lipid A structures for the ions at m/z 1,332, 1,570, and 1,808 are
displayed in Fig. 2. Structure determination was based on the tan-
dem mass spectrometry experiments discussed in detail below. In
addition to the m/z values mentioned above, a number of other
m/z values were observed, which demonstrated the extensive het-
erogeneity of lipid A structures present in lipid A isolated from
WTB. parapertussis LPS (Fig. 2A). Thesem/z values corresponded
to differing phosphorylation and acylation patterns (see Table S1
in the supplemental material for proposed structures of these ad-
ditional ions).
Mass spectrometric analysis of lipid A isolated from B. para-
pertussis pagPmutant LPS. The negative-ion-mode MALDI-TOF
mass spectrum of lipid A isolated from B. parapertussis pagP mu-
tant LPS is shown in Fig. 2B. This lipid A also displayed the most
abundant ion, at m/z 1,332 (Fig. 2B), which corresponded to a
singly deprotonated diphosphoryl tetra-acylated lipid A structure.
Of particular note, ions at m/z 1,570 and 1,808, corresponding to
the addition of one and two secondary C16 acyl chains, respec-
tively, were not present in mutant lipid A. All m/z values for mu-
tant lipid A were also observed for lipid A from WT LPS and
corresponded to identical structures (see Table S1 in the supple-
mental material).
Determination of acyl chain positioning in lipid A isolated
from WT and B. parapertussis pagP mutant LPS using tandem
mass spectrometry. In order to confidently assign structures to
specific m/z values, a series of tandem MS experiments using a
MALDI-TOF/TOF mass spectrometer were performed. In addi-
tion, multistage tandem MS (MSn) experiments were performed
on an ESI LTQ-FT MS platform to further validate structure as-
signment. The gas-phase dissociation of the precursor ion at m/z
1,332 determined via the MALDI-TOF/TOF platform revealed
structure-specific, diagnostic product ions that allowed confident
assignment of the four acyl chains along the lipid A glucosamine
disaccharide (Fig. 3A). Gas-phase dissociation for structure deter-
mination of lipid A via tandem mass spectrometry, whereby struc-
ture-specific, diagnostic product ions are used for structure deter-
mination, was reported previously (12, 28). Of note, the collective
FIG 1 SDS-PAGE LPS profiles of the WT and a B. parapertussis pagP mutant
grown in either the Bvg-plus or Bvg-minus phase and these strains carrying a
plasmid-borne copy of either pagPBPa or pagPBB (Bvg-plus phase only). Lane 1,
WT in the Bvg-plus phase; lane 2, WT in the Bvg-minus phase; lane 3, B.
parapertussis pagP mutant in the Bvg-plus phase; lane 4, B. parapertussis pagP
mutant in the Bvg-minus phase; lane 5, WT in the Bvg-plus phase with
pBBRpagPBPa; lane 6, B. parapertussis pagP mutant in the Bvg-plus phase with
pBBRpagPBPa; lane 7, WT in the Bvg-plus phase with pBBRpagPBB; lane 8, B.
parapertussis pagP mutant in the Bvg-plus phase with pBBRpagPBB.
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analysis of several cross-ring, glycosidic, and competitive neutral
losses of 1° acyl chains yielded a consistent pattern where the four
acyl chains were confidently assigned to the following positions:
amide-linked C14(3-OH) at the C-2 and C-2= positions, ester-
linked C10(3-OH) at the C-3= position, and a secondary C14 ester
linked via the 3-hydroxy position of the C-2 acyl chain (Fig. 2,
structure at m/z 1,332). For example, the product ion at m/z 948.5
corresponded to a 0,2A2 cross-ring fragment that localized the 1°
C10(3-OH) and C14(3-OH) acyl chains and the 2° C14 acyl chain
to the distal (nonreducing) end of the disaccharide. Cross-ring
and glycosidic product ions were named according to the nomen-
clature outlined by Domon and Costello (29), with the slight
modification of designating the loss of neutral acyl chains if
applicable. Next, the cross-ring product ion at m/z 796.4 [0,2A2-
C10(3-OH)ket], presumably a consecutive dissociation from the
ion at m/z 948.5, corresponded to the neutral loss of the 1° C10(3-
OH) as a ketene from the 0,2A2 ion. These product ions deter-
mined that the C-3= position is occupied by the 1° C10(3-OH) acyl
FIG 2 Negative-ion-mode MALDI-TOF mass spectra of lipid A isolated from LPS from the WT (A) and the B. parapertussis pagP mutant (B). Ions at m/z 1,570
and 1,808 represent the addition of one and two 2° C16 acyl chains to the ion at m/z 1,332, respectively. These ions are absent from the mutant lipid A spectrum.
C16, palmitic acid; C10(3-OH), 3-hydroxy capric acid; HPO3, phosphate group. Proposed lipid A structures at m/z values of 1,332, 1,570, and 1,808 are displayed.
In the m/z 1,570 structure, the dashed lines indicate that the palmitate is present as a 2° acyl chain at either the C-2 or C-3= position; i.e., the structure is
penta-acylated.
B. parapertussis pagP
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chain and that the C-2= position contained the 1° C14(3-OH) and
2° C14 acyl chains. In addition, the glycosidic product ion at m/z
484.2 (Y1) squarely indicated that the reducing end of the lipid A
disaccharide contained a 1° C14(3-OH) at the C-2 position. Fur-
ther confirmation of the structure assignment for the ion at m/z
1,332 was demonstrated via the use of tandem mass spectrometry
using an ESI LTQ-FT mass spectrometer, where MSn experiments
were performed (see Fig. S1 in the supplemental material). The
precursor ions at m/z 1,332 from both the WT and the pagP mu-
tant had identical structures.
Structure assignment for the precursor ion at m/z 1,570 corre-
sponded to a diphosphoryl penta-acylated lipid A with acyl chain
assignment as follows: amide-linked C14(3-OH) at the C-2 and
C-2= positions, ester-linked C10(3-OH) at the C-3= position, sec-
ondary C14 ester linked via the 3-hydroxy position of the C-2 acyl
chain, and one secondary C16 ester linked via the 3-hydroxy posi-
tion of the C-2 or the C-3= acyl chain (Fig. 2, structure at m/z
1,570). As described above for the precursor ion at m/z 1,332,
diagnostic product ions which included cross-ring, glycosidic, and
competitive neutral losses of acyl chains were identified and used to
FIG 3 Negative-ion-mode MALDI-TOF/TOF mass spectra for precursor ions at m/z 1,332 (A), m/z 1,570 (B), and m/z 1,808 (C) isolated from WT B.
parapertussis lipid A. Proposed lipid A structures for each precursor ion are shown in each spectrum, with dashed lines representing possible cleavage sites.
Diagnostic cross-ring and glycosidic product ions provided unambiguous structure assignment and were named according to the nomenclature outlined by
Domon and Costello (29), with the slight modification of designating the number of phosphate groups present and the loss of neutral acyl chains if applicable.
All precursor ions were diphosphorylated with a heterogeneous mixture of bisphosphate and pyrophosphate. Only the bisphosphate configuration is displayed.
C16, palmitic acid; C10(3-OH), 3-hydroxy capric acid; C10(3-OH)ket, neutral loss as a ketene; HPO3, phosphate; H3PO4, phosphoric acid; [H3P2O7]
 and
[HP2O6]
, pyrophosphate product ions; [H2PO4]
 and [PO3]
, phosphate product ions.
Hittle et al.
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confidently assign the structure of the ion atm/z1,570 (see Fig. 3B for
identities and m/z values of several diagnostic product ions). Of par-
ticular note, the 2° C16 acyl chain appeared to be localized to the
reducing end (C-2 position), yet conclusive evidence for the exclusive
positioning of the C16 acyl chain was not obtained via MALDI-TOF/
TOF experiments. Further experiments using an ESI LTQ-FT mass
spectrometer capable of higher-order MSn revealed that the 2° C16
acyl chain was localized to either the C-2 or C-3= position (see Fig. S2
in the supplemental material). Given the inherent difficulty of deter-
mining even relative amounts of isomeric structures during ESI mass
spectrometry experiments, determination of the abundance of struc-
tures having a secondary C16 at either the C-2 position or the C-3=
position was not attempted.
Structure assignment for the precursor ion at m/z 1,808 corre-
sponded to a diphosphoryl hexa-acylated lipid A with acyl chain
assignment as follows: amide-linked C14(3-OH) at the C-2 and
C-2= positions, ester-linked C10(3-OH) at the C-3= position, sec-
ondary C14 ester linked via the 3-hydroxy position of the C-2 acyl
chain, and two secondary C16 acyl chains ester linked via the 3-hy-
droxy position of the C-2 and C-3= acyl chains (Fig. 2, structure at
m/z 1,808). Evidence and reasoning analogous to those for the
precursor ions at m/z 1,332 and 1,570 were used to determine the
structure of this ion (Fig. 3C; see also Fig. S3 in the supplemental
material). In effect, diagnostic product ions were identified to
confidently assign the positions of the two 2° C16 acyl chains.
These data demonstrate that B. parapertussis lipid A contains
molecules with either one or two palmitates and that the presence
of palmitate is dependent on pagPBPa. In turn, this strongly sug-
gests that B. parapertussis PagP transfers two palmitate moieties to
lipid A. This is different from B. bronchiseptica PagP, which trans-
fers only a single palmitate. It was possible that the two enzymes
have different transferase abilities, presumably arising from the
single-amino-acid difference between the two enzymes, or that
the different lipid A substrates encountered by the enzymes in the
two hosts direct different transferase activities. To investigate this,
PagPBB was expressed in the B. parapertussis pagP mutant. The B.
bronchiseptica gene was carried on a plasmid and expressed from
its natural promoter (the promoter regions of B. bronchiseptica and
B. parapertussis are identical). This construct was previously used
to complement a B. bronchiseptica pagP mutation (13). Comple-
mentation of the B. parapertussis pagP mutation by pagPBB re-
sulted in a lipid A-core profile identical to that produced by com-
plementation with pagPBPa (Fig. 1, lanes 7 and 8), suggesting that
both the B. parapertussis and B. bronchiseptica enzymes have the
same activity in the B. parapertussis background. To confirm this,
lipid A was purified from both complemented strains and ana-
lyzed by MS (Fig. 4). For both lipid A preparations, ions that
corresponded to molecules containing either a single or two
palmitate additions were detected, demonstrating that PagPBB can
add two palmitates to B. parapertussis lipid A. Thus, both PagPBB
and PagPBPa and have dual functionality, in that they can add
palmitate to two different sites in lipid A. PagPBB does this in B.
parapertussis but not in B. bronchiseptica, and thus, we propose
that the dual functionality is directed by theB. parapertussis lipid A
acceptor substrate.
pagPBPa is required forWT levels of resistance to C18G. The
acylation pattern of lipid A is an important determinant of the
integrity of the outer membrane of Gram-negative bacteria. In
turn, this is important for a range of functions, including resisting
antimicrobial molecules produced by hosts during infection. We
hypothesized that pagPBPa contributes to the ability of the bacte-
rium to resist host antimicrobial peptides, as observed for other
bacterial species. To test this, we measured the level of killing of
the WT and the B. parapertussis pagP mutant after exposure to
C18G, a synthetic 	-helical antimicrobial peptide (30). Approxi-
mately 1 104 CFU of the WT or mutant were incubated with the
peptide (0 to 10 g ml1) for 30 min at 37°C, and the number of
surviving bacteria was enumerated. The results from a represen-
tative experiment are shown in Fig. 5. At each concentration of
peptide, a significantly greater number of mutant bacteria than
WT bacteria were killed. Overall, our data demonstrate that the
WT level of resistance to C18G-mediated killing is dependent on
pagPBPa.
TLR4 stimulation assays. A key activity of lipid A during in-
fection is stimulation of TLR4-mediated signaling. The acylation
pattern of lipid A is a key determinant of this activity. The relative
potencies for stimulation of TLR4-mediated signaling of lipid A
isolated from the WT and pagP mutant strains were measured. A
recombinant reporter system was used (20), expressing either hu-
man or murine TLR4 signaling complexes, as these two systems
recognize and respond to different lipid A structures differently.
Unstimulated cells acted as a negative control. Stimulation with a
known agonist of NF-
B-mediated signaling, interleukin-1 (IL-
1), resulted in relative light unit (RLU) values of 0.54 0.03 and
FIG 4 Mass spectra of the lipid A’s of B. parapertussis pagP complemented
with either pagPBPa (A) or pagPBB (B). Ions corresponding to lipid A with a
single palmitate are indicated by * (m/z 1,570), and those with two palmitates
are indicated by ** (m/z 1,808). Both strains produced identical lipid A’s,
demonstrating that both B. parapertussis PagP and B. bronchiseptica PagP have
dual functionality.
B. parapertussis pagP
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0.59  0.05 for murine and human TLR4-mediated signaling,
respectively, demonstrating the responsiveness of the system.
Stimulation with an E. coli lipid A (1,000 ng/ml) biosynthetic in-
termediate, lipid IVA, which is a strong agonist of murine but not
of human TLR4 signaling, resulted in RLU values of 0.36  0.03
and 0.05 0.00 for murine and human TLR4-mediated signaling,
respectively, and demonstrated that the experimental system
could detect species-specific stimulation.
B. parapertussis WT lipid A was a more potent stimulant of
murine than of human TLR4-mediated signaling (Fig. 6). pagP
mutant lipid A was significantly less potent than the WT for
stimulation of both murine (Fig. 6A) and human (Fig. 6B) TLR4-
mediated signaling but was particularly attenuated for the hu-
man-derived system. These data demonstrate that PagPBPa-medi-
ated modification of B. parapertussis lipid A significantly alters the
endotoxin activity of lipid A toward the human TLR4 signaling
complex.
DISCUSSION
Previously, we characterized B. bronchiseptica PagP as a Bvg-reg-
ulated lipid A palmitoyl transferase and determined that PagP-
mediated palmitoylation was required for resistance to antibody-
dependent complement-mediated killing (13, 15). Here we show
that B. parapertussis PagP is also a Bvg-regulated lipid A palmitoyl
transferase but one that is able to transfer two palmitates to lipid
A, a novel finding. When expressed inB. parapertussis, PagPBB also
mediates the addition of two palmitates to lipid A. We propose
that the lipid A acceptor substrate of B. parapertussis directs this
dual functionality.
Interestingly, the MS analyses presented here demonstrated
FIG 5 B. parapertussis pagP is more susceptible to killing by the synthetic antimicrobial peptide C18G than the WT. A significantly different level of killing of the
WT compared to the pagP mutant was observed. This was observed in three independent experiments; data from a representative experiment are shown here.
FIG6 Stimulation of murine or human TLR4-mediated signaling by WT andB. parapertussis lipid A. Both lipid A’s were more potent stimulators of murine than
of human TLR4-mediated signaling; however, B. parapertussis pagP lipid A was significantly less potent than that of the WT, particularly for the activation of
human TLR4. , P 0.05; , P 0.001.
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considerable lipid A heterogeneity in addition to palmitoylation.
Variability in the presence of C10(3-OH) was observed (Fig. 2).
Ions at m/z 1,162 and 1,400 corresponded to derivatives of the
major tetra- and penta-acylated molecules lacking C10(3-OH),
whereas the ion at m/z 1,502 corresponded to a derivative of the
tetra-acylated molecule that contained an additional C10(3-OH),
presumably at the C-3 position as a result of incomplete deacyla-
tion by PagL (12). Furthermore, each of the peaks corresponding
to the tetra-, penta-, and hexa-acylated species was surrounded by
a series of peaks, each differing from the next by 14 mass units (Fig.
2), corresponding to a series of structures, each differing by one
methylene (CH2) unit. This suggests that B. parapertussis incor-
porates a range of different acyl chains into its lipid A, including
those containing an odd number of carbon atoms. Bordetella
LpxA has relaxed acyl chain specificity that may contribute to this
heterogeneity (31). In turn, this suggests that B. parapertussis lipid
A contains not only three major molecular species but also nu-
merous acylation variants of these major species. A full structural
characterization of this heterogeneity is under way.
PagPBPa mediates the conversion of tetra-acylated to penta-
and hexa-acylated lipid A and thus alters the properties of the
outer membrane. A pagP mutant was more susceptible to direct
killing by an 	-helical antimicrobial peptide (C18G), suggesting
that a loss of palmitoylation affects the integrity or fluidity of the
outer membrane. This has also been observed for Salmonella en-
terica serovar Typhimurium, where a pagP mutant displayed in-
creased outer membrane permeability in response to C18G (32).
PagP-mediated palmitoylation results in an altered potency of
B. parapertussis lipid A for stimulating signaling via TLR4. WT
lipid A was more proinflammatory than pagP mutant lipid A,
particularly via the human-derived signaling complex. When con-
sidering the basis for the effect of palmitoylation on lipid A po-
tency, it is important to consider that the individual lipid A prep-
arations are comprised of a mixture of lipid A molecules and that
the overall potency is the sum of their individual potencies, which
may include some antagonistic activities. Either way, the Bvg-reg-
ulated expression of pagPBPa appears to confer on B. parapertussis
a mechanism by which to regulate the potency of its lipid A for
TLR4 stimulation. The Bvg phase, in which PagPBPa appears to
be maximally expressed, is thought to be that adopted by the bac-
teria during infection. In this case, our data suggest that both
singly and doubly palmitoylated lipid A will be synthesized and
that lipid A is at its most potent, compared to the Bvg-minus
phase. However, B. parapertussis has low-potency lipid A com-
pared to that of B. bronchiseptica, and it has been demonstrated in
mice that B. parapertussis avoids invoking host immune responses
through the lack of stimulation of TLR4-mediated signaling (33).
This suggests that Bvg-mediated regulation of lipid A potency
does not play a role during infection.
Clearly, the in vitro system used here does not reveal the precise
immune response stimulated by either palmitoylated or non-
palmitoylated lipid A during infection, and thus, the conse-
quences of regulating the level of lipid A palmitoylation are not
clear. In addition, our data demonstrate that PagP activity regu-
lates outer membrane function in other ways, such as resistance to
host antimicrobial peptides, and that the bacterium may have to
balance increased lipid A potency for TLR4 stimulation versus
inherent resistance to immune effector molecules. In support of
this, B. bronchiseptica pagP is required for persistent colonization
of the mouse respiratory tract (13). However, a pagPBB mutant
appears to colonize similarly to the WT during the early course of
infection, with attenuation manifesting only between days 3 and 7
postinoculation, perhaps suggesting that there is little difference
in early events when innate immunity resulting from TLR4 stim-
ulation is operational. Furthermore, we demonstrated that pagPBB
is required for resistance to antibody-dependent complement-
mediated lysis (15), suggesting that the major role of pagP in B.
bronchiseptica is to contribute to the integrity of the outer mem-
brane.
It is also of interest to consider the difference in lipid A biosyn-
thetic enzymes betweenBordetella subspecies.B. pertussis,B. bron-
chiseptica, and B. parapertussis share a very similar set of lipid A
biosynthesis and modification genes, but they each synthesize spe-
cies-specific lipid A’s (34). Some genes are mutated in one species
(e.g., pagP in B. pertussis [13]), while subtle allelic differences re-
sult in differences in activity among species, e.g., lpxA (31). Here
our data suggest that slight alterations in the lipid A structure can
direct different activities of enzymes common to more than one
species. Presumably, the evolution of these three species in their
different niches and different infection biologies has selected for
these subtly different combinations of lipid A biosynthesis activi-
ties. Thus, while the regulated expression of Bordetella pagP sug-
gests that B. parapertussis may modulate its lipid A structure dur-
ing infection, the extent to which this happens and the
consequences of it require analyses in vivo, with consideration of
the different potencies of stimulation of B. parapertussis lipid A
toward TLR4 from different hosts.
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